Market Cap (In JPY)
5.54 Billion
Revenue (In JPY)
69.25 Million
Net Income (In JPY)
-854.15 Million
Avg. Volume
261.62 Thousand
- Currency
- JPY
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 394.0-1328.0
- PE
- -
- EPS
- -
- Beta Value
- 0.342
- ISIN
- JP3270790003
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Kiichi Adachi Ph.D.
- Employee Count
- -
- Website
- https://www.kringle-pharma.com
- Ipo Date
- 2020-12-28
- Details
- Kringle Pharma, Inc. engages in the research and development, manufactures, and sells hepatocyte growth factor (HGF) protein pharmaceuticals for regenerative medicines. The company develops HGF products for the treatment of acute spinal cord injury, amyotrophic lateral sclerosis, vocal fold scar, and acute kidney injury. Kringle Pharma, Inc. was incorporated in 2001 and is based in Ibaraki, Japan.
More Stocks
-
AEI
-
HACBFThe Hachijuni Bank, Ltd.
HACBF
-
PNBHOUSINGPNB Housing Finance Limited
PNBHOUSING
-
HLEE
-
0954
-
CIGNITITECCigniti Technologies Limited
CIGNITITEC
-
8275
-
BARRABarramundi Group Ltd.
BARRA